US 11,723,932 B2
Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
Dean Falb, Sherborn, MA (US); Jonathan W. Kotula, Somerville, MA (US); Vincent M. Isabella, Cambridge, MA (US); Paul F. Miller, Salem, CT (US); Suman Machinani, Cambridge, MA (US); Saurabh Saha, Wellesley Hills, MA (US); Adam B. Fisher, Cambridge, MA (US); Yves Millet, Newton, MA (US); and Ning Li, Winchester, MA (US)
Assigned to Synlogic Operating Company, Inc., Cambridge, MA (US)
Appl. No. 16/69,220
Filed by Synlogic Operating Company, Inc., Cambridge, MA (US)
PCT Filed Jan. 11, 2017, PCT No. PCT/US2017/013072
§ 371(c)(1), (2) Date Jul. 11, 2018,
PCT Pub. No. WO2017/123675, PCT Pub. Date Jul. 20, 2017.
Application 16/069,220 is a continuation in part of application No. 15/164,828, filed on May 25, 2016, granted, now 9,688,967.
Application 15/164,828 is a continuation in part of application No. PCT/US2016/034200, filed on May 25, 2016.
Application PCT/US2016/034200 is a continuation in part of application No. PCT/US2016/032565, filed on May 13, 2016.
Claims priority of provisional application 62/443,639, filed on Jan. 6, 2017.
Claims priority of provisional application 62/439,871, filed on Dec. 28, 2016.
Claims priority of provisional application 62/423,170, filed on Nov. 16, 2016.
Claims priority of provisional application 62/385,235, filed on Sep. 8, 2016.
Claims priority of provisional application 62/362,954, filed on Jul. 15, 2016.
Claims priority of provisional application 62/354,682, filed on Jun. 24, 2016.
Claims priority of provisional application 62/348,360, filed on Jun. 10, 2016.
Claims priority of provisional application 62/348,699, filed on Jun. 10, 2016.
Claims priority of provisional application 62/347,567, filed on Jun. 8, 2016.
Claims priority of provisional application 62/347,508, filed on Jun. 8, 2016.
Claims priority of provisional application 62/335,940, filed on May 13, 2016.
Claims priority of provisional application 62/314,322, filed on Mar. 28, 2016.
Claims priority of provisional application 62/313,691, filed on Mar. 25, 2016.
Claims priority of provisional application 62/305,462, filed on Mar. 8, 2016.
Claims priority of provisional application 62/297,778, filed on Feb. 19, 2016.
Claims priority of provisional application 62/293,749, filed on Feb. 10, 2016.
Claims priority of provisional application 62/277,455, filed on Jan. 11, 2016.
Claims priority of provisional application 62/277,450, filed on Jan. 11, 2016.
Prior Publication US 2019/0160115 A1, May 30, 2019
Int. Cl. A01N 63/00 (2020.01); A61K 35/74 (2015.01); C07K 16/28 (2006.01); A61P 35/00 (2006.01); C07K 14/54 (2006.01); C12N 15/70 (2006.01); C12P 13/22 (2006.01); A61K 38/20 (2006.01); C12N 15/00 (2006.01); C12N 5/00 (2006.01); C07K 14/34 (2006.01); A61K 31/00 (2006.01); C07K 14/335 (2006.01); C07K 14/245 (2006.01); A61K 39/395 (2006.01); C07K 14/535 (2006.01); C07K 14/55 (2006.01); A61K 48/00 (2006.01); A61K 38/19 (2006.01); C12P 21/02 (2006.01); A61K 39/00 (2006.01)
CPC A61K 35/74 (2013.01) [A61K 31/00 (2013.01); A61K 38/193 (2013.01); A61K 38/20 (2013.01); A61K 39/3955 (2013.01); A61K 39/39541 (2013.01); A61K 48/00 (2013.01); A61P 35/00 (2018.01); C07K 14/245 (2013.01); C07K 14/335 (2013.01); C07K 14/34 (2013.01); C07K 14/535 (2013.01); C07K 14/54 (2013.01); C07K 14/5434 (2013.01); C07K 14/5443 (2013.01); C07K 14/55 (2013.01); C07K 16/2803 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C12N 5/00 (2013.01); C12N 15/00 (2013.01); C12N 15/70 (2013.01); C12P 13/227 (2013.01); C12P 21/02 (2013.01); A61K 2039/505 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2319/03 (2013.01); C07K 2319/036 (2013.01); C07K 2319/40 (2013.01)] 7 Claims
 
1. A genetically engineered non-pathogenic microorganism for intratumoral administration comprising a gene sequence for producing kynureninase, wherein the gene sequence is operably linked to an inducible promoter, and wherein the bacterium further comprises an aroP, tnaB, or mtr gene sequence encoding a transporter for importing kynurenine into the bacterium; and wherein the bacterium is an auxotroph comprising a deletion in a thyA, dapD, or dapA gene.